CARGO Therapeutics (CRGX) Q2 2024 earnings summary

Executive summary

• Clinical-stage biotech focused on next-gen cell therapies for cancer, with lead program firi-cel in Phase 2 for large B-cell lymphoma post-CD19 CAR T failure; all 31 sites activated and 38 patients dosed in pivotal FIRCE-1 study, with interim analysis expected in H1 2025.

• Net loss of $44.3M for Q2 2024 and $80.2M for H1 2024; accumulated deficit reached $225.3M as of June 30, 2024.

• Cash, cash equivalents, and marketable securities totaled $443.5M as of June 30, 2024, expected to fund operations through 2026.

• Raised $110M in May 2024 PIPE financing, with net proceeds of $102.9M; no products approved or revenue from product sales to date.

• Jane Pritchett Henderson joined the Board in June 2024, bringing strategic finance experience.

Financial highlights

• Q2 2024 research and development expenses were $37.5M, with $1.7M in non-cash stock-based compensation; H1 2024 R&D totaled $68.0M.

• General and administrative expenses were $11.9M for Q2 2024 and $22.2M for H1 2024, including $2.6M and $4.8M in non-cash stock-based compensation.

• Interest/other income was $5.0M in Q2 2024, up from $0.6M in Q2 2023, reflecting higher cash balances post-IPO and private placement.

• Net loss per share was $(1.02) for Q2 2024, compared to $(26.56) in Q2 2023, reflecting increased share count post-IPO.

• Operating expenses for Q2 2024 were $49.3M; for the first half, $90.1M.

Outlook and guidance

• Current cash and marketable securities expected to fund operations through 2026 based on current plans.

• Interim analysis of the FIRCE-1 Phase 2 study is expected in the first half of 2025.

• Anticipates continued significant operating losses as clinical and preclinical programs advance and headcount grows.

• Expects to seek additional capital if needed, with future funding requirements dependent on clinical progress, regulatory milestones, and potential commercialization.